Bibliography
- TRACEY KJ, CERAMI A: Tumor necrosis factor: a pleio- tropic cytokine and therapeutic target. Ann. Rev. Med. (1994) 45:491–503.
- AGGARWAL BB, NATARAJAN K: Tumor necrosis factors: developments during the last decade. Eur. Cyt. Netw. (1996) 7:93–124.
- PASPARAKIS M, ALEXOPOULOU L et al.: Immune and in-flammatory responses in TNFa-deficient mice: a criti-cal requirement for TNFa in the formation of primary B cell follicles, follicular dendritic cell networks and erminal centers, and in the maturation of humoral immune response. J. Exp. Med. (1996) 184:1397–1411.
- MARRIOTT JB, WESTBY M, DALGLEISH AG: Therapeutic potential of TNF inhibitors old and new. Drug Disc. To-day (1997) 2:273–282.
- BADGER AM, LEE JC: Advances in antiarthritic thera- peutics. Drug Disc. Today (1997) 2:427–435.
- SHIRE MG, MULLER GW: TNF-a inhibitors and rheuma-toid arthritis. Exp. Opin. Ther. Patents (1998) 8:531–544.
- BLACK RA, BIRD TA, MOHLER KM: Agents that block TNF-a synthesis or activity. In: Annual Report on Medici-nal Chemistry. Academic Press (1997):241–250.
- STEIN B, ANDERSON D: The MAP kinase family: New 'MAPS' for signal transduction pathways and novel tar-gets for drug discovery. In: Annual Report on Medicinal Chemistry. Academic Press (1996)289–290.
- LEE JC, LAYDON JT, MCDONNELL PC et al:A protein ki-nase involved in the regulation of inflammatory cyto-kine biosynthesis. Nature (1994) 372:739–746.
- This landmark paper describes the role of human p38 MAPKand its role in cytokine regulation.
- BOEHM JC, SMIETANA JM, SORENSON ME: 1-Substituted 4-aryl-5-pyridinylimidazoles: a new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclo-oxygenase inhibitory potency. J. Med. Chem. (1996) 39:3929–3937.
- This paper describes other substitution patterns of imidazoles-based anti-inflammatory agents.
- BADGER AM, BRADBEER JM, VOTTA B et al.: Pharma- cological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endo-toxin shock and immune function. J. Pharm. Exp. Ther. (1996) 279:1453–1461.
- This paper validates the effectiveness of this class of com-pounds in animal models of inflammation.
- TONG L, PAV S, WHITE DM et al.: A highly specific in- hibitor of human p38 MAP kinase binds in the ATP pocket. Nat. Struct. Biol. (1997) 4:311–316.
- This paper describes the x-ray crystallographic binding in-teractions of a SB 19203580 analogue with p38.